On May 8, 2023, Beijing Luzhu Biotechnology Co., Ltd. (Luzhu Biotechnology) successfully listed on the Main Board of the Stock Exchange of Hong Kong, raising approximately HK$340.7 million (US$43.4 million) from a global offering of 10,386,000 H shares. Luzhu Biotechnology is a biotechnology company committed to developing innovative vaccines and therapeutic biologics to prevent and control infectious diseases and treat cancer and autoimmune diseases. Since the beginning of 2023, Luzhu Biotechnology is the first pre-revenue biotech company listed on the Hong Kong Stock Exchange pursuant to Chapter 18A of the Listing Rules.

Wilson Sonsini Goodrich & Rosati acted as U.S. and Hong Kong counsel to the sole sponsor (China International Capital Corporation Hong Kong Securities Limited) and the underwriters in the global offering and listing.

The Wilson Sonsini team includes:

Corporate
Dan Ouyang
Winfield Lau
Ke Li
Xinyi Wang
Claire Chen
Celia Li
Giselle Ma
Rong Ma
Hera Poon 

Patents and Innovations
Richard Wang

Tax
Myra A. Sutanto Shen
Nika Antonikova

For more information, please see Luzhu Biotechnology’s investor relations page.